PH030

PH030 is a small molecule modulator of the apelin pathway currently in preclinical development by Suzhou Puzheng Pharma (also known as Puhe Biopharma) for the treatment of metabolic diseases. The apelin system, which includes the apelin peptide and its cognate G protein-coupled receptor (APLNR or APJ), is a critical regulator of various physiological processes, including cardiovascular homeostasis, fluid balance, and glucose metabolism. By targeting the apelin receptor, PH030 aims to address underlying dysfunctions in metabolic conditions. As of current development stages, the specific functional profile of PH030 as either an agonist or antagonist has not been publicly specified.